Xyosted

Drug Overview

In the field of Endocrinology, the management of male hypogonadism has traditionally relied on intramuscular injections or topical gels, both of which can present challenges regarding patient comfort, hormonal fluctuations, and safety concerns like secondary transfer. Xyosted represents a significant technological advancement in Hormone Replacement Therapy (HRT). It is a specialized, pre-filled autoinjector designed for patient-administered delivery of testosterone.

As a potent Androgen, Xyosted utilizes a unique subcutaneous (under the skin) delivery system that provides a steady release of the hormone, aiming to maintain physiological testosterone levels while minimizing the “peaks and valleys” often associated with traditional deep-muscle injections.

• Generic Name / Active Ingredient: Testosterone Enanthate
• US Brand Name: Xyosted
• Drug Class: Androgen; Schedule III Controlled Substance
• Route of Administration: Subcutaneous Injection (Autoinjector)
• FDA Approval Status: Fully FDA-approved for testosterone replacement therapy in adult males.

What Is It and How Does It Work? (Mechanism of Action)

Xyosted acts as a bioidentical form of Hormone Replacement Therapy. The active ingredient, testosterone enanthate, is an ester of the naturally occurring male androgen. The enanthate ester is designed to slow the release of testosterone from the injection site into the bloodstream.

Molecular and Hormonal Level

The mechanism follows the classic androgenic signaling pathway, but is distinguished by its subcutaneous absorption profile:

1. Subcutaneous Depot Formation: Upon injection into the fatty tissue of the abdomen, the medication forms a small reservoir (depot). Unlike intramuscular injections that are absorbed rapidly due to high blood flow in muscles, the subcutaneous route allows for a more gradual, controlled diffusion.
2. Ester Cleavage: Once in the circulation, plasma esterases cleave the enanthate side chain, releasing pure testosterone.
3. Nuclear Receptor Binding: Testosterone (or its metabolite Dihydrotestosterone) enters target cells and binds to the Androgen Receptor.
4. Genomic Regulation: The hormone-receptor complex moves into the cell nucleus, where it binds to DNA to trigger the transcription of genes responsible for male secondary sexual characteristics, muscle protein synthesis, and maintaining Bone Mineral Density (BMD).
5. HPG Axis Suppression: Through negative feedback, exogenous testosterone suppresses the Hypothalamic-Pituitary-Adrenal (HPA) Axis—specifically inhibiting the release of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH).

FDA-Approved Clinical Indications

Primary Indication

The primary use of Xyosted is for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone:

• Primary Hypogonadism (Congenital or Acquired): Testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, or Klinefelter’s syndrome.
• Hypogonadotropic Hypogonadism (Congenital or Acquired): Idiopathic gonadotropin or LHRH deficiency or pituitary-hypothalamic injury.

Other Approved & Off-Label Uses

• Gender-Affirming Care: Increasingly utilized as a Targeted Therapy for masculine hormone transition in transgender men due to the ease of self-administration.
• Hormonal Stabilization: Used in research contexts to determine if subcutaneous delivery reduces the risk of polycythemia (excess red blood cells) compared to intramuscular routes.

Primary Endocrinology Indications:

• Androgen Restoration: Normalizing serum testosterone to improve libido, energy, and mood.
• Metabolic Improvement: Enhancing Insulin Sensitivity and lean body mass while reducing visceral fat.

Dosage and Administration Protocols

Xyosted is a once-weekly injection. It is available in three strengths (50 mg, 75 mg, and 100 mg) to allow for precise titration.

Administration Timing and Technique

• Injection Site: Must be injected only into the abdomen.
• Technique: The autoinjector is a single-use, disposable device. It should be pressed against the skin until the “click” is heard, and held for a full 10 seconds to ensure the full dose is delivered.
• Titration: Total testosterone levels should be measured approximately 6 weeks after starting therapy. The blood draw should occur mid-week (3 to 5 days after a dose) to ensure accurate maintenance levels.

Dosage must be individualized by a qualified healthcare professional.

Clinical Efficacy and Research Results

Clinical data from the 2020–2026 era demonstrates that Xyosted provides a highly stable pharmacokinetic profile.

• Serum Concentration: In pivotal trials, approximately 90% of men achieved a mean total testosterone concentration in the normal range ( 300  to  1100  ng/dL) with once-weekly dosing.
• Symptom Relief: Research indicates a statistically significant improvement in the Psychosexual Questionnaire (PDQ) scores, including sexual desire and erectile function, within 12 weeks of initiation.
• Bone Health: Longitudinal data suggests a mean increase in Bone Mineral Density of 1.5% to 2% annually in hypogonadal men.
• Consistency: Unlike traditional IM injections where levels spike high and then drop low before the next dose, Xyosted maintained levels with a low “peak-to-trough” ratio, reducing the incidence of “mood crashes.”

Safety Profile and Side Effects

BLACK BOX WARNING: BLOOD PRESSURE INCREASES

Xyosted can cause blood pressure (BP) increases that can increase the risk of major adverse cardiovascular events (MACE), including heart attack and stroke. BP should be monitored prior to initiating therapy and periodically during treatment.

Common Side Effects (> 10\% )

• Injection Site Reactions: Redness, bruising, or mild pain at the abdominal site.
• Hypertension: Elevated blood pressure.
• Acne: Increased oil production in the skin.

Serious Adverse Events

• Polycythemia: An increase in red blood cell count (Hematocrit).
• Prostate Health: Potential increase in PSA (Prostate-Specific Antigen); may worsen symptoms of Benign Prostatic Hyperplasia (BPH).
• Venous Thromboembolism (VTE): Risk of blood clots in the legs or lungs.
• Depression/Anxiety: New or worsening mood disorders.

Management Strategies: Regular monitoring of Hematocrit, PSA, and blood pressure is mandatory. If BP cannot be controlled with medication, Xyosted may need to be discontinued.

Research Areas

Direct Clinical Connections

Active research in 2025–2026 is focusing on the interaction between subcutaneous testosterone and Insulin Sensitivity. Preliminary data suggests that the stable levels provided by Xyosted may be more effective at reducing HbA1c in diabetic men than traditional “spiking” injections.

Generalization & Advancements

The development of Novel Delivery Systems, including even smaller autoinjectors and “smart” tracking apps that sync with the device, is a major focus. Researchers are also evaluating the use of Xyosted in the prevention of Macrovascular Complications in high-risk metabolic patients.

Disclaimer: Information regarding the potential for subcutaneous testosterone to be more effective at reducing HbA1c in diabetic men than traditional IM injections, as well as its role in preventing macrovascular complications via stable hormonal signaling, should be considered exploratory unless supported by definitive clinical evidence. While these represent significant frontiers in the optimization of TRT and metabolic health, they are not yet applicable to all clinical scenarios or standard of care protocols.

Patient Management and Clinical Protocols

Pre-treatment Assessment

• Baseline Diagnostics: Two morning (8:00 AM) total testosterone levels.
• Cardiovascular Risk: Baseline blood pressure and lipid panel.
• Organ Function: Liver function and baseline Hematocrit.
• Screening: PSA and Digital Rectal Exam (DRE).

Monitoring and Precautions

• Vigilance: Monitor for signs of heart failure (edema, shortness of breath).
• Laboratory Monitoring: Trough testosterone, PSA, and Hematocrit every 3 to 6 months.

“Do’s and Don’ts”

• DO inject on the same day every week.
• DO rotate the injection site around the abdomen to prevent skin thickening.
• DO check your blood pressure at home regularly.
• DON’T inject into the muscle or genitals.
• DON’T use the device if the liquid is cloudy or contains particles.
• DON’T share your autoinjector with anyone else.

Legal Disclaimer

This guide is for informational purposes only and does not constitute medical advice. Xyosted is a Schedule III controlled substance and must be managed by a board-certified Endocrinologist. Do not start or change your dose without a professional consultation. Data is accurate as of April 2026.